 | • レポートコード：MRC2Q12-16843 • 出版社/出版日：QYResearch / 2022年12月 • レポート形態：英文、PDF、111ページ • 納品方法：Eメール（納期：3営業日） • 産業分類：医療 |
| Single User | ￥725,200 (USD4,900) | ▷ お問い合わせ |
| Enterprise License | ￥1,450,400 (USD9,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| コロナ禍により、肉腫治療薬剤の世界市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx％で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年に肉腫治療薬剤のグローバル市場のxxx％を占める「ビンクリスチン」タイプは、2028年までにUS$xxxの規模になり、パンデミック後の修正xxx％CAGRで成長すると予測されています。一方、「病院」セグメントは、この予測期間を通じてxxx％のCAGRに変更されます。 肉腫治療薬剤の中国市場規模は2021年にUS$xxxと分析されており、アメリカとヨーロッパの市場規模はそれぞれUS$xxxとUS$xxxです。アメリカの割合は2021年にxxx％であり、中国とヨーロッパはそれぞれxxx％とxxx％です。中国の割合は2028年にxxx％に達し、対象期間を通じてxxx％のCAGRを記録すると予測されています。日本、韓国、東南アジアはアジアで注目市場であり、今後6年間のCAGRはそれぞれxxx％、xxx％、xxx％になる見通しです。ヨーロッパの肉腫治療薬剤市場については、ドイツは2028年までにUS$xxxに達すると予測されており、予測期間中のCAGRはxxx％になる見通しです。 肉腫治療薬剤のグローバル主要プレイヤーには、Novartis、Pfizer、Eisai、Johnson & Johnson、Bayer、Roche、GSK、Teva Pharmaceuticals、Celgene、Bristol Myers Squibb、BeiGene、Shenzhen Chipscreen、Monopar Therapeutics、Akeso Biopharmaなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx％の市場シェアを占めています。 肉腫治療薬剤市場は、種類と用途によって区分されます。世界の肉腫治療薬剤市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年～2028年期間のタイプ別および用途別の販売量、売上、予測に焦点を当てています。 【種類別セグメント】 ビンクリスチン、シクロホスファミド、ドキソルビシン、その他 【用途別セグメント】 病院、がんセンター、その他 【掲載地域】 北米：アメリカ、カナダ ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア アジア太平洋：日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア 中南米：メキシコ、ブラジル、アルゼンチン 中東・アフリカ：トルコ、サウジアラビア、UAE 【目次（一部）】 ・調査の範囲 - 肉腫治療薬剤製品概要 - 種類別市場（ビンクリスチン、シクロホスファミド、ドキソルビシン、その他） - 用途別市場（病院、がんセンター、その他） - 調査の目的 ・エグゼクティブサマリー - 世界の肉腫治療薬剤販売量予測2017-2028 - 世界の肉腫治療薬剤売上予測2017-2028 - 肉腫治療薬剤の地域別販売量 - 肉腫治療薬剤の地域別売上 - 北米市場 - ヨーロッパ市場 - アジア太平洋市場 - 中南米市場 - 中東・アフリカ市場 ・メーカーの競争状況 - 主要メーカー別肉腫治療薬剤販売量 - 主要メーカー別肉腫治療薬剤売上 - 主要メーカー別肉腫治療薬剤価格 - 競争状況の分析 - 企業M&A動向 ・種類別市場規模（ビンクリスチン、シクロホスファミド、ドキソルビシン、その他） - 肉腫治療薬剤の種類別販売量 - 肉腫治療薬剤の種類別売上 - 肉腫治療薬剤の種類別価格 ・用途別市場規模（病院、がんセンター、その他） - 肉腫治療薬剤の用途別販売量 - 肉腫治療薬剤の用途別売上 - 肉腫治療薬剤の用途別価格 ・北米市場 - 北米の肉腫治療薬剤市場規模（種類別、用途別） - 主要国別の肉腫治療薬剤市場規模（アメリカ、カナダ） ・ヨーロッパ市場 - ヨーロッパの肉腫治療薬剤市場規模（種類別、用途別） - 主要国別の肉腫治療薬剤市場規模（ドイツ、フランス、イギリス、イタリア、ロシア） ・アジア太平洋市場 - アジア太平洋の肉腫治療薬剤市場規模（種類別、用途別） - 主要国別の肉腫治療薬剤市場規模（日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア） ・中南米市場 - 中南米の肉腫治療薬剤市場規模（種類別、用途別） - 主要国別の肉腫治療薬剤市場規模（メキシコ、ブラジル、アルゼンチン） ・中東・アフリカ市場 - 中東・アフリカの肉腫治療薬剤市場規模（種類別、用途別） - 主要国別の肉腫治療薬剤市場規模（トルコ、サウジアラビア） ・企業情報 Novartis、Pfizer、Eisai、Johnson & Johnson、Bayer、Roche、GSK、Teva Pharmaceuticals、Celgene、Bristol Myers Squibb、BeiGene、Shenzhen Chipscreen、Monopar Therapeutics、Akeso Biopharma ・産業チェーン及び販売チャネル分析 - 肉腫治療薬剤の産業チェーン分析 - 肉腫治療薬剤の原材料 - 肉腫治療薬剤の生産プロセス - 肉腫治療薬剤の販売及びマーケティング - 肉腫治療薬剤の主要顧客 ・マーケットドライバー、機会、課題、リスク要因分析 - 肉腫治療薬剤の産業動向 - 肉腫治療薬剤のマーケットドライバー - 肉腫治療薬剤の課題 - 肉腫治療薬剤の阻害要因 ・主な調査結果 |
Report Overview
Due to the COVID-19 pandemic and Russia-Ukraine War Influence, the global market for Sarcoma Drugs estimated at US$ million in the year 2022, is projected to reach a revised size of US$ million by 2028, growing at a CAGR of % during the forecast period 2022-2028.
The USA market for Sarcoma Drugs is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The China market for Sarcoma Drugs is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The Europe market for Sarcoma Drugs is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The global key companies of Sarcoma Drugs include Novartis, Pfizer, Eisai, Johnson & Johnson, Bayer, Roche, GSK, Teva Pharmaceuticals and Celgene, etc. In 2021, the global top five players had a share approximately % in terms of revenue.
Report Scope
This latest report researches the industry structure, revenue and gross margin. Major players’ headquarters, market shares, industry ranking and profiles are presented. The primary and secondary research is done in order to access up-to-date government regulations, market information and industry data. Data were collected from the Sarcoma Drugs companies, distributors, end users, industry associations, governments’ industry bureaus, industry publications, industry experts, third party database, and our in-house databases.
This report also includes a discussion of the major players across each regional Sarcoma Drugs market. Further, it explains the major drivers and regional dynamics of the global Sarcoma Drugs market and current trends within the industry.
Key Companies Covered
In this section of the report, the researchers have done a comprehensive analysis of the prominent players operating and the strategies they are focusing on to combat the intense competition. Company profiles and market share analysis of the prominent players are also provided in this section. Additionally, the specialists have done an all-encompassing analysis of each player. They have also provided reliable revenue, market share and rank data of the companies for the period 2017-2022. With the assistance of this report, key players, stakeholders, and other participants will be able to stay abreast of the recent and upcoming developments in the business, further enabling them to make efficient choices. Mentioned below are the prime players taken into account in this research report:
Novartis
Pfizer
Eisai
Johnson & Johnson
Bayer
Roche
GSK
Teva Pharmaceuticals
Celgene
Bristol Myers Squibb
BeiGene
Shenzhen Chipscreen
Monopar Therapeutics
Akeso Biopharma
Market Segments
This report has explored the key segments: by Type and by Application. The lucrativeness and growth potential have been looked into by the industry experts in this report. This report also provides revenue forecast data by type and by application segments based on value for the period 2017-2028.
Sarcoma Drugs Segment by Type
Vincristine
Cyclophosphamide
Doxorubicin
Others
Sarcoma Drugs Segment by Application
Hospitals
Oncology Centers
Others
Key Regions & Countries
This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the value data of each region and country for the period 2017-2028.
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the Sarcoma Drugs market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management, export and import, and production. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
Report Includes:
This report presents an overview of global market for Sarcoma Drugs market size. Analyses of the global market trends, with historic market revenue data for 2017 – 2021, estimates for 2022, and projections of CAGR through 2028.
This report researches the key producers of Sarcoma Drugs, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Sarcoma Drugs, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Sarcoma Drugs revenue, market share and industry ranking of main companies, data from 2017 to 2022. Identification of the major stakeholders in the global Sarcoma Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, revenue, and growth rate, from 2017 to 2028. Evaluation and forecast the market size for Sarcoma Drugs revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Novartis, Pfizer, Eisai, Johnson & Johnson, Bayer, Roche, GSK, Teva Pharmaceuticals and Celgene, etc.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Sarcoma Drugs in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Sarcoma Drugs companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments according to product types, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments according to application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America by type, by application and by country, revenue for each segment.
Chapter 7: Europe by type, by application and by country, revenue for each segment.
Chapter 8: Asia Pacific by type, by application and by country/region, revenue for each segment.
Chapter 9: Latin America by type, by application and by country, revenue for each segment.
Chapter 10: Middle East and Africa by type, by application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Sarcoma Drugs revenue, gross margin, and recent development, etc.
Chapter 12: Analyst’s Viewpoints/Conclusions
1 Report Business Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Sarcoma Drugs Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Vincristine
1.2.3 Cyclophosphamide
1.2.4 Doxorubicin
1.2.5 Others
1.3 Market by Application
1.3.1 Global Sarcoma Drugs Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Hospitals
1.3.3 Oncology Centers
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Sarcoma Drugs Market Perspective (2017-2028)
2.2 Sarcoma Drugs Growth Trends by Region
2.2.1 Sarcoma Drugs Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Sarcoma Drugs Historic Market Size by Region (2017-2022)
2.2.3 Sarcoma Drugs Forecasted Market Size by Region (2023-2028)
2.3 Sarcoma Drugs Market Dynamics
2.3.1 Sarcoma Drugs Industry Trends
2.3.2 Sarcoma Drugs Market Drivers
2.3.3 Sarcoma Drugs Market Challenges
2.3.4 Sarcoma Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Sarcoma Drugs Players by Revenue
3.1.1 Global Top Sarcoma Drugs Players by Revenue (2017-2022)
3.1.2 Global Sarcoma Drugs Revenue Market Share by Players (2017-2022)
3.2 Global Sarcoma Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Sarcoma Drugs Revenue
3.4 Global Sarcoma Drugs Market Concentration Ratio
3.4.1 Global Sarcoma Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Sarcoma Drugs Revenue in 2021
3.5 Sarcoma Drugs Key Players Head office and Area Served
3.6 Key Players Sarcoma Drugs Product Solution and Service
3.7 Date of Enter into Sarcoma Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Sarcoma Drugs Breakdown Data by Type
4.1 Global Sarcoma Drugs Historic Market Size by Type (2017-2022)
4.2 Global Sarcoma Drugs Forecasted Market Size by Type (2023-2028)
5 Sarcoma Drugs Breakdown Data by Application
5.1 Global Sarcoma Drugs Historic Market Size by Application (2017-2022)
5.2 Global Sarcoma Drugs Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Sarcoma Drugs Market Size (2017-2028)
6.2 North America Sarcoma Drugs Market Size by Type
6.2.1 North America Sarcoma Drugs Market Size by Type (2017-2022)
6.2.2 North America Sarcoma Drugs Market Size by Type (2023-2028)
6.2.3 North America Sarcoma Drugs Market Share by Type (2017-2028)
6.3 North America Sarcoma Drugs Market Size by Application
6.3.1 North America Sarcoma Drugs Market Size by Application (2017-2022)
6.3.2 North America Sarcoma Drugs Market Size by Application (2023-2028)
6.3.3 North America Sarcoma Drugs Market Share by Application (2017-2028)
6.4 North America Sarcoma Drugs Market Size by Country
6.4.1 North America Sarcoma Drugs Market Size by Country (2017-2022)
6.4.2 North America Sarcoma Drugs Market Size by Country (2023-2028)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Sarcoma Drugs Market Size (2017-2028)
7.2 Europe Sarcoma Drugs Market Size by Type
7.2.1 Europe Sarcoma Drugs Market Size by Type (2017-2022)
7.2.2 Europe Sarcoma Drugs Market Size by Type (2023-2028)
7.2.3 Europe Sarcoma Drugs Market Share by Type (2017-2028)
7.3 Europe Sarcoma Drugs Market Size by Application
7.3.1 Europe Sarcoma Drugs Market Size by Application (2017-2022)
7.3.2 Europe Sarcoma Drugs Market Size by Application (2023-2028)
7.3.3 Europe Sarcoma Drugs Market Share by Application (2017-2028)
7.4 Europe Sarcoma Drugs Market Size by Country
7.4.1 Europe Sarcoma Drugs Market Size by Country (2017-2022)
7.4.2 Europe Sarcoma Drugs Market Size by Country (2023-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Sarcoma Drugs Market Size (2017-2028)
8.2 Asia-Pacific Sarcoma Drugs Market Size by Type
8.2.1 Asia-Pacific Sarcoma Drugs Market Size by Type (2017-2022)
8.2.2 Asia-Pacific Sarcoma Drugs Market Size by Type (2023-2028)
8.2.3 Asia-Pacific Sarcoma Drugs Market Share by Type (2017-2028)
8.3 Asia-Pacific Sarcoma Drugs Market Size by Application
8.3.1 Asia-Pacific Sarcoma Drugs Market Size by Application (2017-2022)
8.3.2 Asia-Pacific Sarcoma Drugs Market Size by Application (2023-2028)
8.3.3 Asia-Pacific Sarcoma Drugs Market Share by Application (2017-2028)
8.4 Asia-Pacific Sarcoma Drugs Market Size by Region
8.4.1 Asia-Pacific Sarcoma Drugs Market Size by Region (2017-2022)
8.4.2 Asia-Pacific Sarcoma Drugs Market Size by Region (2023-2028)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Sarcoma Drugs Market Size (2017-2028)
9.2 Latin America Sarcoma Drugs Market Size by Type
9.2.1 Latin America Sarcoma Drugs Market Size by Type (2017-2022)
9.2.2 Latin America Sarcoma Drugs Market Size by Type (2023-2028)
9.2.3 Latin America Sarcoma Drugs Market Share by Type (2017-2028)
9.3 Latin America Sarcoma Drugs Market Size by Application
9.3.1 Latin America Sarcoma Drugs Market Size by Application (2017-2022)
9.3.2 Latin America Sarcoma Drugs Market Size by Application (2023-2028)
9.3.3 Latin America Sarcoma Drugs Market Share by Application (2017-2028)
9.4 Latin America Sarcoma Drugs Market Size by Country
9.4.1 Latin America Sarcoma Drugs Market Size by Country (2017-2022)
9.4.2 Latin America Sarcoma Drugs Market Size by Country (2023-2028)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Sarcoma Drugs Market Size (2017-2028)
10.2 Middle East & Africa Sarcoma Drugs Market Size by Type
10.2.1 Middle East & Africa Sarcoma Drugs Market Size by Type (2017-2022)
10.2.2 Middle East & Africa Sarcoma Drugs Market Size by Type (2023-2028)
10.2.3 Middle East & Africa Sarcoma Drugs Market Share by Type (2017-2028)
10.3 Middle East & Africa Sarcoma Drugs Market Size by Application
10.3.1 Middle East & Africa Sarcoma Drugs Market Size by Application (2017-2022)
10.3.2 Middle East & Africa Sarcoma Drugs Market Size by Application (2023-2028)
10.3.3 Middle East & Africa Sarcoma Drugs Market Share by Application (2017-2028)
10.4 Middle East & Africa Sarcoma Drugs Market Size by Country
10.4.1 Middle East & Africa Sarcoma Drugs Market Size by Country (2017-2022)
10.4.2 Middle East & Africa Sarcoma Drugs Market Size by Country (2023-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Novartis
11.1.1 Novartis Company Details
11.1.2 Novartis Business Overview
11.1.3 Novartis Sarcoma Drugs Introduction
11.1.4 Novartis Revenue in Sarcoma Drugs Business (2017-2022)
11.1.5 Novartis Recent Developments
11.2 Pfizer
11.2.1 Pfizer Company Details
11.2.2 Pfizer Business Overview
11.2.3 Pfizer Sarcoma Drugs Introduction
11.2.4 Pfizer Revenue in Sarcoma Drugs Business (2017-2022)
11.2.5 Pfizer Recent Developments
11.3 Eisai
11.3.1 Eisai Company Details
11.3.2 Eisai Business Overview
11.3.3 Eisai Sarcoma Drugs Introduction
11.3.4 Eisai Revenue in Sarcoma Drugs Business (2017-2022)
11.3.5 Eisai Recent Developments
11.4 Johnson & Johnson
11.4.1 Johnson & Johnson Company Details
11.4.2 Johnson & Johnson Business Overview
11.4.3 Johnson & Johnson Sarcoma Drugs Introduction
11.4.4 Johnson & Johnson Revenue in Sarcoma Drugs Business (2017-2022)
11.4.5 Johnson & Johnson Recent Developments
11.5 Bayer
11.5.1 Bayer Company Details
11.5.2 Bayer Business Overview
11.5.3 Bayer Sarcoma Drugs Introduction
11.5.4 Bayer Revenue in Sarcoma Drugs Business (2017-2022)
11.5.5 Bayer Recent Developments
11.6 Roche
11.6.1 Roche Company Details
11.6.2 Roche Business Overview
11.6.3 Roche Sarcoma Drugs Introduction
11.6.4 Roche Revenue in Sarcoma Drugs Business (2017-2022)
11.6.5 Roche Recent Developments
11.7 GSK
11.7.1 GSK Company Details
11.7.2 GSK Business Overview
11.7.3 GSK Sarcoma Drugs Introduction
11.7.4 GSK Revenue in Sarcoma Drugs Business (2017-2022)
11.7.5 GSK Recent Developments
11.8 Teva Pharmaceuticals
11.8.1 Teva Pharmaceuticals Company Details
11.8.2 Teva Pharmaceuticals Business Overview
11.8.3 Teva Pharmaceuticals Sarcoma Drugs Introduction
11.8.4 Teva Pharmaceuticals Revenue in Sarcoma Drugs Business (2017-2022)
11.8.5 Teva Pharmaceuticals Recent Developments
11.9 Celgene
11.9.1 Celgene Company Details
11.9.2 Celgene Business Overview
11.9.3 Celgene Sarcoma Drugs Introduction
11.9.4 Celgene Revenue in Sarcoma Drugs Business (2017-2022)
11.9.5 Celgene Recent Developments
11.10 Bristol Myers Squibb
11.10.1 Bristol Myers Squibb Company Details
11.10.2 Bristol Myers Squibb Business Overview
11.10.3 Bristol Myers Squibb Sarcoma Drugs Introduction
11.10.4 Bristol Myers Squibb Revenue in Sarcoma Drugs Business (2017-2022)
11.10.5 Bristol Myers Squibb Recent Developments
11.11 BeiGene
11.11.1 BeiGene Company Details
11.11.2 BeiGene Business Overview
11.11.3 BeiGene Sarcoma Drugs Introduction
11.11.4 BeiGene Revenue in Sarcoma Drugs Business (2017-2022)
11.11.5 BeiGene Recent Developments
11.12 Shenzhen Chipscreen
11.12.1 Shenzhen Chipscreen Company Details
11.12.2 Shenzhen Chipscreen Business Overview
11.12.3 Shenzhen Chipscreen Sarcoma Drugs Introduction
11.12.4 Shenzhen Chipscreen Revenue in Sarcoma Drugs Business (2017-2022)
11.12.5 Shenzhen Chipscreen Recent Developments
11.13 Monopar Therapeutics
11.13.1 Monopar Therapeutics Company Details
11.13.2 Monopar Therapeutics Business Overview
11.13.3 Monopar Therapeutics Sarcoma Drugs Introduction
11.13.4 Monopar Therapeutics Revenue in Sarcoma Drugs Business (2017-2022)
11.13.5 Monopar Therapeutics Recent Developments
11.14 Akeso Biopharma
11.14.1 Akeso Biopharma Company Details
11.14.2 Akeso Biopharma Business Overview
11.14.3 Akeso Biopharma Sarcoma Drugs Introduction
11.14.4 Akeso Biopharma Revenue in Sarcoma Drugs Business (2017-2022)
11.14.5 Akeso Biopharma Recent Developments
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer
Table 1. Global Sarcoma Drugs Market Size Growth Rate by Type (US$ Million), 2017 VS 2021 VS 2028
Table 2. Key Players of Vincristine
Table 3. Key Players of Cyclophosphamide
Table 4. Key Players of Doxorubicin
Table 5. Key Players of Others
Table 6. Global Sarcoma Drugs Market Size Growth Rate by Application (US$ Million), 2017 VS 2021 VS 2028
Table 7. Global Sarcoma Drugs Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
Table 8. Global Sarcoma Drugs Market Size by Region (2017-2022) & (US$ Million)
Table 9. Global Sarcoma Drugs Market Share by Region (2017-2022)
Table 10. Global Sarcoma Drugs Forecasted Market Size by Region (2023-2028) & (US$ Million)
Table 11. Global Sarcoma Drugs Market Share by Region (2023-2028)
Table 12. Sarcoma Drugs Market Trends
Table 13. Sarcoma Drugs Market Drivers
Table 14. Sarcoma Drugs Market Challenges
Table 15. Sarcoma Drugs Market Restraints
Table 16. Global Sarcoma Drugs Revenue by Players (2017-2022) & (US$ Million)
Table 17. Global Sarcoma Drugs Revenue Share by Players (2017-2022)
Table 18. Global Top Sarcoma Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Sarcoma Drugs as of 2021)
Table 19. Ranking of Global Top Sarcoma Drugs Companies by Revenue (US$ Million) in 2021
Table 20. Global 5 Largest Players Market Share by Sarcoma Drugs Revenue (CR5 and HHI) & (2017-2022)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Sarcoma Drugs Product Solution and Service
Table 23. Date of Enter into Sarcoma Drugs Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Sarcoma Drugs Market Size by Type (2017-2022) & (US$ Million)
Table 26. Global Sarcoma Drugs Revenue Market Share by Type (2017-2022)
Table 27. Global Sarcoma Drugs Forecasted Market Size by Type (2023-2028) & (US$ Million)
Table 28. Global Sarcoma Drugs Revenue Market Share by Type (2023-2028)
Table 29. Global Sarcoma Drugs Market Size by Application (2017-2022) & (US$ Million)
Table 30. Global Sarcoma Drugs Revenue Share by Application (2017-2022)
Table 31. Global Sarcoma Drugs Forecasted Market Size by Application (2023-2028) & (US$ Million)
Table 32. Global Sarcoma Drugs Revenue Share by Application (2023-2028)
Table 33. North America Sarcoma Drugs Market Size by Type (2017-2022) & (US$ Million)
Table 34. North America Sarcoma Drugs Market Size by Type (2023-2028) & (US$ Million)
Table 35. North America Sarcoma Drugs Market Size by Application (2017-2022) & (US$ Million)
Table 36. North America Sarcoma Drugs Market Size by Application (2023-2028) & (US$ Million)
Table 37. North America Sarcoma Drugs Market Size by Country (2017-2022) & (US$ Million)
Table 38. North America Sarcoma Drugs Market Size by Country (2023-2028) & (US$ Million)
Table 39. Europe Sarcoma Drugs Market Size by Type (2017-2022) & (US$ Million)
Table 40. Europe Sarcoma Drugs Market Size by Type (2023-2028) & (US$ Million)
Table 41. Europe Sarcoma Drugs Market Size by Application (2017-2022) & (US$ Million)
Table 42. Europe Sarcoma Drugs Market Size by Application (2023-2028) & (US$ Million)
Table 43. Europe Sarcoma Drugs Market Size by Country (2017-2022) & (US$ Million)
Table 44. Europe Sarcoma Drugs Market Size by Country (2023-2028) & (US$ Million)
Table 45. Asia Pacific Sarcoma Drugs Market Size by Type (2017-2022) & (US$ Million)
Table 46. Asia Pacific Sarcoma Drugs Market Size by Type (2023-2028) & (US$ Million)
Table 47. Asia Pacific Sarcoma Drugs Market Size by Application (2017-2022) & (US$ Million)
Table 48. Asia Pacific Sarcoma Drugs Market Size by Application (2023-2028) & (US$ Million)
Table 49. Asia Pacific Sarcoma Drugs Market Size by Region (2017-2022) & (US$ Million)
Table 50. Asia Pacific Sarcoma Drugs Market Size by Region (2023-2028) & (US$ Million)
Table 51. Latin America Sarcoma Drugs Market Size by Type (2017-2022) & (US$ Million)
Table 52. Latin America Sarcoma Drugs Market Size by Type (2023-2028) & (US$ Million)
Table 53. Latin America Sarcoma Drugs Market Size by Application (2017-2022) & (US$ Million)
Table 54. Latin America Sarcoma Drugs Market Size by Application (2023-2028) & (US$ Million)
Table 55. Latin America Sarcoma Drugs Market Size by Country (2017-2022) & (US$ Million)
Table 56. Latin America Sarcoma Drugs Market Size by Country (2023-2028) & (US$ Million)
Table 57. Middle East and Africa Sarcoma Drugs Market Size by Type (2017-2022) & (US$ Million)
Table 58. Middle East and Africa Sarcoma Drugs Market Size by Type (2023-2028) & (US$ Million)
Table 59. Middle East and Africa Sarcoma Drugs Market Size by Application (2017-2022) & (US$ Million)
Table 60. Middle East and Africa Sarcoma Drugs Market Size by Application (2023-2028) & (US$ Million)
Table 61. Middle East and Africa Sarcoma Drugs Market Size by Country (2017-2022) & (US$ Million)
Table 62. Middle East and Africa Sarcoma Drugs Market Size by Country (2023-2028) & (US$ Million)
Table 63. Novartis Company Details
Table 64. Novartis Business Overview
Table 65. Novartis Sarcoma Drugs Product
Table 66. Novartis Revenue in Sarcoma Drugs Business (2017-2022) & (US$ Million)
Table 67. Novartis Recent Developments
Table 68. Pfizer Company Details
Table 69. Pfizer Business Overview
Table 70. Pfizer Sarcoma Drugs Product
Table 71. Pfizer Revenue in Sarcoma Drugs Business (2017-2022) & (US$ Million)
Table 72. Pfizer Recent Developments
Table 73. Eisai Company Details
Table 74. Eisai Business Overview
Table 75. Eisai Sarcoma Drugs Product
Table 76. Eisai Revenue in Sarcoma Drugs Business (2017-2022) & (US$ Million)
Table 77. Eisai Recent Developments
Table 78. Johnson & Johnson Company Details
Table 79. Johnson & Johnson Business Overview
Table 80. Johnson & Johnson Sarcoma Drugs Product
Table 81. Johnson & Johnson Revenue in Sarcoma Drugs Business (2017-2022) & (US$ Million)
Table 82. Johnson & Johnson Recent Developments
Table 83. Bayer Company Details
Table 84. Bayer Business Overview
Table 85. Bayer Sarcoma Drugs Product
Table 86. Bayer Revenue in Sarcoma Drugs Business (2017-2022) & (US$ Million)
Table 87. Bayer Recent Developments
Table 88. Roche Company Details
Table 89. Roche Business Overview
Table 90. Roche Sarcoma Drugs Product
Table 91. Roche Revenue in Sarcoma Drugs Business (2017-2022) & (US$ Million)
Table 92. Roche Recent Developments
Table 93. GSK Company Details
Table 94. GSK Business Overview
Table 95. GSK Sarcoma Drugs Product
Table 96. GSK Revenue in Sarcoma Drugs Business (2017-2022) & (US$ Million)
Table 97. GSK Recent Developments
Table 98. Teva Pharmaceuticals Company Details
Table 99. Teva Pharmaceuticals Business Overview
Table 100. Teva Pharmaceuticals Sarcoma Drugs Product
Table 101. Teva Pharmaceuticals Revenue in Sarcoma Drugs Business (2017-2022) & (US$ Million)
Table 102. Teva Pharmaceuticals Recent Developments
Table 103. Celgene Company Details
Table 104. Celgene Business Overview
Table 105. Celgene Sarcoma Drugs Product
Table 106. Celgene Revenue in Sarcoma Drugs Business (2017-2022) & (US$ Million)
Table 107. Celgene Recent Developments
Table 108. Bristol Myers Squibb Company Details
Table 109. Bristol Myers Squibb Business Overview
Table 110. Bristol Myers Squibb Sarcoma Drugs Product
Table 111. Bristol Myers Squibb Revenue in Sarcoma Drugs Business (2017-2022) & (US$ Million)
Table 112. Bristol Myers Squibb Recent Developments
Table 113. BeiGene Company Details
Table 114. BeiGene Business Overview
Table 115. BeiGene Sarcoma Drugs Product
Table 116. BeiGene Revenue in Sarcoma Drugs Business (2017-2022) & (US$ Million)
Table 117. BeiGene Recent Developments
Table 118. Shenzhen Chipscreen Company Details
Table 119. Shenzhen Chipscreen Business Overview
Table 120. Shenzhen Chipscreen Sarcoma Drugs Product
Table 121. Shenzhen Chipscreen Revenue in Sarcoma Drugs Business (2017-2022) & (US$ Million)
Table 122. Shenzhen Chipscreen Recent Developments
Table 123. Monopar Therapeutics Company Details
Table 124. Monopar Therapeutics Business Overview
Table 125. Monopar Therapeutics Sarcoma Drugs Product
Table 126. Monopar Therapeutics Revenue in Sarcoma Drugs Business (2017-2022) & (US$ Million)
Table 127. Monopar Therapeutics Recent Developments
Table 128. Akeso Biopharma Company Details
Table 129. Akeso Biopharma Business Overview
Table 130. Akeso Biopharma Sarcoma Drugs Product
Table 131. Akeso Biopharma Revenue in Sarcoma Drugs Business (2017-2022) & (US$ Million)
Table 132. Akeso Biopharma Recent Developments
Table 133. Research Programs/Design for This Report
Table 134. Key Data Information from Secondary Sources
Table 135. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Sarcoma Drugs Market Share by Type: 2021 VS 2028
Figure 2. Vincristine Features
Figure 3. Cyclophosphamide Features
Figure 4. Doxorubicin Features
Figure 5. Others Features
Figure 6. Global Sarcoma Drugs Market Share by Application: 2021 VS 2028
Figure 7. Hospitals Case Studies
Figure 8. Oncology Centers Case Studies
Figure 9. Others Case Studies
Figure 10. Sarcoma Drugs Report Years Considered
Figure 11. Global Sarcoma Drugs Market Size (US$ Million), Year-over-Year: 2017-2028
Figure 12. Global Sarcoma Drugs Market Size, (US$ Million), 2017 VS 2021 VS 2028
Figure 13. Global Sarcoma Drugs Market Share by Region: 2021 VS 2028
Figure 14. Global Sarcoma Drugs Market Share by Players in 2021
Figure 15. Global Top Sarcoma Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Sarcoma Drugs as of 2021)
Figure 16. The Top 10 and 5 Players Market Share by Sarcoma Drugs Revenue in 2021
Figure 17. North America Sarcoma Drugs Market Size YoY (2017-2028) & (US$ Million)
Figure 18. North America Sarcoma Drugs Market Size Market Share by Type (2017-2028)
Figure 19. North America Sarcoma Drugs Market Size Market Share by Application (2017-2028)
Figure 20. North America Sarcoma Drugs Market Size Share by Country (2017-2028)
Figure 21. United States Sarcoma Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 22. Canada Sarcoma Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 23. Europe Sarcoma Drugs Market Size YoY (2017-2028) & (US$ Million)
Figure 24. Europe Sarcoma Drugs Market Size Market Share by Type (2017-2028)
Figure 25. Europe Sarcoma Drugs Market Size Market Share by Application (2017-2028)
Figure 26. Europe Sarcoma Drugs Market Size Share by Country (2017-2028)
Figure 27. Germany Sarcoma Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 28. France Sarcoma Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 29. U.K. Sarcoma Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 30. Italy Sarcoma Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 31. Russia Sarcoma Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 32. Nordic Countries Sarcoma Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 33. Asia-Pacific Sarcoma Drugs Market Size YoY (2017-2028) & (US$ Million)
Figure 34. Asia Pacific Sarcoma Drugs Market Size Market Share by Type (2017-2028)
Figure 35. Asia Pacific Sarcoma Drugs Market Size Market Share by Application (2017-2028)
Figure 36. Asia Pacific Sarcoma Drugs Market Size Share by Region (2017-2028)
Figure 37. China Sarcoma Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 38. Japan Sarcoma Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 39. South Korea Sarcoma Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 40. Southeast Asia Sarcoma Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 41. India Sarcoma Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 42. Australia Sarcoma Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 43. Latin America Sarcoma Drugs Market Size YoY (2017-2028) & (US$ Million)
Figure 44. Latin America Sarcoma Drugs Market Size Market Share by Type (2017-2028)
Figure 45. Latin America Sarcoma Drugs Market Size Market Share by Application (2017-2028)
Figure 46. Latin America Sarcoma Drugs Market Size Share by Country (2017-2028)
Figure 47. Mexico Sarcoma Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 48. Brazil Sarcoma Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 49. Middle East & Africa Sarcoma Drugs Market Size YoY (2017-2028) & (US$ Million)
Figure 50. Middle East and Africa Sarcoma Drugs Market Size Market Share by Type (2017-2028)
Figure 51. Middle East and Africa Sarcoma Drugs Market Size Market Share by Application (2017-2028)
Figure 52. Middle East and Africa Sarcoma Drugs Market Size Share by Country (2017-2028)
Figure 53. Turkey Sarcoma Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 54. Saudi Arabia Sarcoma Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 55. UAE Sarcoma Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 56. Novartis Revenue Growth Rate in Sarcoma Drugs Business (2017-2022)
Figure 57. Pfizer Revenue Growth Rate in Sarcoma Drugs Business (2017-2022)
Figure 58. Eisai Revenue Growth Rate in Sarcoma Drugs Business (2017-2022)
Figure 59. Johnson & Johnson Revenue Growth Rate in Sarcoma Drugs Business (2017-2022)
Figure 60. Bayer Revenue Growth Rate in Sarcoma Drugs Business (2017-2022)
Figure 61. Roche Revenue Growth Rate in Sarcoma Drugs Business (2017-2022)
Figure 62. GSK Revenue Growth Rate in Sarcoma Drugs Business (2017-2022)
Figure 63. Teva Pharmaceuticals Revenue Growth Rate in Sarcoma Drugs Business (2017-2022)
Figure 64. Celgene Revenue Growth Rate in Sarcoma Drugs Business (2017-2022)
Figure 65. Bristol Myers Squibb Revenue Growth Rate in Sarcoma Drugs Business (2017-2022)
Figure 66. BeiGene Revenue Growth Rate in Sarcoma Drugs Business (2017-2022)
Figure 67. Shenzhen Chipscreen Revenue Growth Rate in Sarcoma Drugs Business (2017-2022)
Figure 68. Monopar Therapeutics Revenue Growth Rate in Sarcoma Drugs Business (2017-2022)
Figure 69. Akeso Biopharma Revenue Growth Rate in Sarcoma Drugs Business (2017-2022)
Figure 70. Bottom-up and Top-down Approaches for This Report
Figure 71. Data Triangulation
Figure 72. Key Executives Interviewed